<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660488</url>
  </required_header>
  <id_info>
    <org_study_id>18-000665</org_study_id>
    <secondary_id>20181796</secondary_id>
    <nct_id>NCT03660488</nct_id>
  </id_info>
  <brief_title>Cefixime for Alternative Syphilis Treatment</brief_title>
  <official_title>Clinical Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to evaluate the efficacy of oral cefixime as an alternative
      treatment for syphilis infection.

      One hundred adult patients (≥18 years old) with syphilis infection (positive Treponema
      Pallidum Particle Agglutination assay and RPR titer ≥ 1/8) will be recruited. Participants
      will be randomized (1:1) to receive either the standard of care Penicillin or Cefixime.

      During the study, participants will visit the clinic up to 5 times; at baseline visit, at 3,
      6, 12 months after treatment initiation. Participants of the cefixime group will be required
      to visit the clinic 14 days after treatment initiation. In each visit, participants will be
      asked about current symptoms and do laboratory tests for syphilis (RPR). Subjects who have a
      4-fold decrease (from study entry RPR) in RPR titers from baseline at 6 months will be
      considered a positive treatment response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Syphilis is a major issue worldwide causing 5.6 million new cases of syphilis worldwide, of
      which over 900,000 are pregnant women. It is also responsible for congenital infections
      causing fetal loss or stillbirth or, in a live-born infant, neonatal death, prematurity and
      low birth weight. Penicillin is the currently used treatment. However, lack of penicillin and
      alternatives to treatment often hinder treatment and prevention efforts.

      Cefixime is an FDA-approved, orally administered third-generation cephalosporin that is
      currently used for the treatment of a wide range of infections, including urinary tract
      infections. Our goal is to evaluate the efficacy and safety of oral cefixime as an
      alternative treatment for syphilis infection.

      One hundred adult patients (≥18 years old) with syphilis infection will be recruited.
      Eligible participants will have laboratory-confirmed syphilis infection with a positive
      Treponema pallidum Particle Agglutination (TPPA) assay and RPR (Rapid Plasma Reagin ) titer ≥
      1/8. Participants will be randomized (1:1) to receive either the standard of care Penicillin
      or Cefixime.

      During the study, participants will visit the clinic 5 times; at baseline visit, demographic,
      clinical information and laboratory test results for syphilis will be recorded and treatment
      will start. Depending on the study group, the treatment plan will be oral Cefixime 400mg,
      twice per day for ten consecutive days or one dose of intramuscular Penicillin. Patients will
      be required to visit the clinic two weeks after treatment initiation to verify adverse
      effects. Follow up visits will occur at 3, 6 and 12 months after treatment initiation. In
      each visit, participants will be asked about current symptoms, interval sexual history,
      concomitant antibiotic use and possible adverse reactions. Subjects will also have a
      venipuncture blood specimen collected for syphilis testing (RPR). Subjects who have a 4-fold
      decrease (from study entry RPR) in RPR titers from baseline at 6 months will be considered a
      positive treatment response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response</measure>
    <time_frame>6 months after treatment completion</time_frame>
    <description>subjects who have a 4-fold decrease (from study entry RPR) in RPR titers from baseline at 3 or 6 months will be considered a positive treatment response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Syphilis</condition>
  <condition>Early Syphilis</condition>
  <arm_group>
    <arm_group_label>Benzathine Penicillin G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients of the &quot;Penicillin Group&quot; will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefixime Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of the &quot;Cefixime Group&quot; will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.
The group will consist of 50 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefixime 400 milligram Oral Capsule [Suprax]</intervention_name>
    <description>The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days</description>
    <arm_group_label>Cefixime Group</arm_group_label>
    <other_name>Suprax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzathine Penicillin G</intervention_name>
    <description>The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection</description>
    <arm_group_label>Benzathine Penicillin G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older and able to provide informed consent

          2. Cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3
             weeks prior to enrollment.

          3. HIV infected individuals willing to participate in the study must have CD4 count ≥350
             cells/μl within the last 4 weeks and be virally suppressed (i.e., viral load ≤ 200
             copies/mL) for HIV for the 6 months prior to enrolment with the most recent results
             within the last 4 weeks. inclusion

          4. Non-cephalosporin allergic

          5. Able to travel to the clinic once a day or be available for phone calls or receive
             text messages for at least 7-10 days and willing to attend follow-up visits

          6. Able to swallow pills

        Exclusion Criteria:

          1. Pregnancy or positive pregnancy test

          2. Serofast RPR titer (prior titer 1:8 or greater)

          3. Recent (less than 7 days) or concomitant antimicrobial therapy with activity against
             syphilis.

          4. Cephalosporin allergy: previous episode of flushing, urticaria, angioedema, rhinitis,
             bronchospasm, and anaphylactic shock, rash after taking cephalosporin.

          5. Penicillin allergy: previous episode of flushing, urticaria, angioedema, rhinitis,
             bronchospasm, and anaphylactic shock, rash after receiving Penicillin.

          6. Has a medical condition or other factor that might affect their ability to follow the
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey D Klausner, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Tellalian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Helthcare Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey D Klausner, MD MPH</last_name>
    <phone>3107943221</phone>
    <email>jdklausner@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chrysovalantis Stafylis, MD MPH</last_name>
    <email>cstafylis@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AHF Westside</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Millner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Downtown Healthcare Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tellalian, MD</last_name>
      <email>david.tellalian@aidshealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Carl Bean</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tellalian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Hollywood Healthcare Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Burian, PA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Wellness on Western Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cliff Okada, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Oakland Wellness Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Mejia, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Healthcare Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Glassman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Glassman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Valley</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Carroll, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Las Vegas Healthcare Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Warren Magnus, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Jeffrey D. Klausner, MD, MPH</investigator_full_name>
    <investigator_title>Professor of Medicine &amp; Public Health</investigator_title>
  </responsible_party>
  <keyword>syphilis</keyword>
  <keyword>cefixime</keyword>
  <keyword>penicillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Cefixime</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the sensitive nature of the data, participant data will not be provided or shared with other researchers, apart from the members of the research team or regulatory authorities</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

